

<p>FORM HDP-1449 (Based on Form PTO-1449)</p> <p>PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)</p> <p>Sheet 1 of 6</p>	ATTORNEY DOCKET NO.	SERIAL No.
	6102-000048/US/NP	10/593,964
	APPLICANT	
	Scheller, D. , <i>et al.</i>	
	FILING DATE	GROUP
	September 22, 2006	1627

U.S. PATENT DOCUMENTS						
Ref. Desig.	Examiner's Initials	Document Number	Publication Date	Name	Class/ Subclass	Filing Date
		2004/0116537	Jun 17, 2004	Li, <i>et al.</i>	514/663	Nov 17, 2003
		2004/0198753	Oct 7, 2004	Kase <i>et al.</i>	514/263.2	Jan 28, 2003
		2005/0182090	Aug 18, 2005	Mierau <i>et al.</i>	514/304	Jan 21, 2005
		2005/0197385	Sep 8, 2005	Scheller, <i>et al.</i>	514/438	Feb 17, 2005
		4,542,135	Sep 17, 1985	Kobel <i>et al.</i>	514/250	Aug 03, 1982
		4,564,628	Jan 14, 1986	Horn	514/438	Aug 13, 1984
		4,722,933	Feb 02, 1988	Horn	514/438	Mar 17, 1986
		4,824,860	Apr 25, 1989	Owen	514/418	May 19, 1988
		4,847,253	Jul 11, 1989	Buonamici <i>et al.</i>	514/253	Nov 18, 1988
		4,885,308	Dec 05, 1989	Horn	514/438	Jun 13, 1988
		5,071,875	Dec 10, 1991	Horn	514/613	Sep 25, 1989
		5,151,446	Sep 29, 1992	Horn <i>et al.</i>	514/617	Mar 28, 1991
		5,234,945	Aug 10, 1993	Belluzzi		Jan 4, 1991
		5,456,745	Oct 10, 1995	Roreger <i>et al.</i>	106/128	Aug 11, 1989
		5,486,611	Jan 23, 1996	Lin <i>et al.</i>	546/62	Oct 28, 1993
		5,496,843	Mar 05, 1996	Nagata <i>et al.</i>	514/411	Nov 14, 1994
		5,545,755	Aug 13, 1996	Lin <i>et al.</i>	564/428	Jan 18, 1995
		5,614,518	Mar 25, 1997	Leeson <i>et al.</i>	514/234.5	Nov 21, 1994
		5,633,376	May 27, 1997	Thurkauf & Hutchinson	544/360	Sep 27, 1994
		5,681,956	Oct 28, 1997	Thurkauf & Hutchison	544/295	Mar 9, 1995
		5,807,570	Sep 15, 1998	Chen <i>et al.</i>	424/449	Sep 04, 1996
		5,807,855	Sep 15, 1998	Bogeso <i>et al.</i>	514/449	Oct 28, 1994
		5,891,461	Apr 06, 1999	Jona <i>et al.</i>	424/449	Sep 14, 1995
		6,001,861	Dec 14, 1999	Oertel <i>et al.</i>	514/367	Jan 16, 1998
		6,010,877	Jan 04, 2000	Sathe <i>et al.</i>	435/69.1	Jan 10, 1997
		6,107,318	Aug 22, 2000	Pocchiari <i>et al.</i>	514/367	Jan 16, 1998
		6,221,627	Apr 24, 2001	Sathe <i>et al.</i>	435/69.1	Feb 24, 1997

Examiner: /Sahar Javanmard/	Date Considered: 09/02/2010
-----------------------------	-----------------------------

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.J./

<p>FORM HDP-1449 (Based on Form PTO-1449)</p> <p>PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)</p> <p>Sheet 2 of 6</p>	ATTORNEY DOCKET NO.	SERIAL NO.
	6102-000048/US/NP	10/593,964
	APPLICANT	
	Scheller, D., <i>et al.</i>	
	FILING DATE	GROUP
	September 22, 2006	1627

U.S. PATENT DOCUMENTS						
Ref. Desig.	Examiner's Initials	Document Number	Publication Date	Name	Class/ Subclass	Filing Date
		6,227,875	Aug 21, 2001	Holman	514/367	Jul 17, 2000
		6,331,636	Dec 18, 2001	Romero & Darlington	548/235	Mar 22, 1992
		7,632,859	Dec 15, 2009	Li <i>et al.</i>	514/438	Nov 17, 2003

FOREIGN PATENT DOCUMENTS							
Ref. Desig.	Examiner's Initials	Document Number	Date	Country	Class/ Subclass	Translation Yes	No
		CA 2 532 804	Feb 03, 2005	CA	A61K		
		CA 2 532 859	Feb 03, 2005	CA	A61K		
		CA 2 547 820	Jun 30, 2005	CA	A61K		
		CA 2 568 850	Feb 16, 2006	CA	CO7D		
		WO 93/00313	Jan 07, 1993	PCT	A61K		
		WO 94/26703	Nov 24, 1994	PCT	CO7C		
		WO 97/29735	Aug 21, 1997	PCT	A61K		
		WO 00/02053	Jun 13, 2000	PCT	GOIN		
		WO 00/03715	Jan 27, 2000	PCT	A61K		
		WO 00/35954	Jun 22, 2000	PCT	CO7K		
		WO 00/38669	Jul 06, 2000	PCT	A61K		
		WO 01/38321	May 31, 2001	PCT	CO7D		
		WO 01/39756	Jun 07, 2001	PCT	A61K		
		WO 01/62249	Aug 30, 2001	PCT	A61K		
		WO 02/18382	Jul 03, 2002	PCT	CO7D		
		WO 03/007803	Jan 30, 2003	PCT	A61B		

Examiner: /Sahar Javanmard/	Date Considered: 09/02/2010
-----------------------------	-----------------------------

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.J./

<p>FORM HDP-1449 (Based on Form PTO-1449)</p> <p>PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)</p> <p>Sheet 3 of 6</p>	ATTORNEY DOCKET No.	SERIAL No.
	6102-000048/US/NP	10/593,964
	APPLICANT	
	Scheller, D., <i>et al.</i>	
	FILING DATE	GROUP
	September 22, 2006	1627

FOREIGN PATENT DOCUMENTS							
Ref. Desig.	Examiner's Initials	Document Number	Date	Country	Class/ Subclass	Translation Yes	No
		WO 03/012137	Feb 13, 2003	PCT	C12Q	X	
		WO 03/029233	Apr 10, 2003	PCT	CO7D		
		WO 03/069332	Aug 21, 2003	PCT	A61K		
		WO 03/076658	Sep 18, 2003	PCT	C12Q		
		WO 03/088958	Oct 30, 2003	PCT	A61K		
		WO 04/012719	Feb 12, 2004	PCT	A61K		
		WO 06/039532	Apr 13, 2006	PCT	A61K		
		WO 04/050083	Jun 17, 2004	PCT	A61K		
		WO 06/050976	Mar 18, 2006	PCT	CO7D	X	
		EP 1256339	Nov 13, 2002	EPO	A61K		

Examiner: /Sahar Javanmard/	Date Considered: 09/02/2010
-----------------------------	-----------------------------

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.J./

FORM HDP-1449 (Based on Form PTO-1449) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) Sheet 4 of 6	ATTORNEY DOCKET NO.	SERIAL NO.
	6102-000048/US/NP	10/593,964
	APPLICANT	
	Scheller, D., <i>et al.</i>	
	FILING DATE	GROUP
	September 22, 2006	1627

OTHER DOCUMENTS		
Ref. Desig.	Examiner's Initials	
		Abbas (1999) Hum. Mol. Genet 8, 567
		Balsara <i>et al.</i> (1982) Ind. J. Physiol. Pharmac. 26(3):1&3495
		Barzilai (2001) Cell Mol. Neurobiol. 21(3), 215-235
		Becker (2002) J. Neurol. 249(Suppl. 3) III/40-III/48
		Blanchet <i>et al.</i> (2004) Parkinsonism and Related Disorders 10, 297-304
		Borsini (1988) Eur. J. Pharmacol. 148, 301-307
		Burn (2000) The Pharmaceutical Journal 264, 476-479
		Camicioli (2002) R. Drugs Today (Barc) 38*10, 677-686
		Carp <i>et al.</i> (1982) Brain Research 242, 247-254
		Chan <i>et al.</i> (2004) Hospital Pharmacist 11, 18-22
		Chase <i>et al.</i> (1995) Clinical Neuropharmacology 18(1), S207-S215
		Collado-Seidet <i>et al.</i> (1999) CNS Drugs 12(1):9-20
		Domino <i>et al.</i> (1993) J. Pharmacol. & Experimental Therapy Vol 264(1), 221-225
		EMEA (2005) Scientific discussim (SioI), www.emea.wropa.eu/humandoCSmDFsIEPAFVsif I/ 0591 97ei16.M~ 9 pp.
		Foley <i>et al.</i> (2004) J. Neural Transmission 111, 1375-1446
		Gerlach <i>et al.</i> (2003) J. Neural Transm. 65(Suppl.), 167-183
		Guttman (2003) Canadian Med. Assoc. Journal 168(3), 293-301
		Hackling (2002) ChemBioChem 3, 947-961
		Hagan <i>et al.</i> (1997) TIPS Vol 18, 156-163
		Hauser <i>et al.</i> (2004) Neurol. Clin. 22, S149-S166
		Henderson (2003) J. Neurol. Neurosurg. Psychiatry 74, 956
		Hoehn (1992) <u>Parkinson's Disease</u> 10(2):331-339
		Holcomb <i>et al.</i> (1982) Eur. J. Pharmacol. 82, 173-178
		Hornykiewicz (2002) Encyclopedia of Life Sciences Vol 13, 695-704
		Hughes (1992) J. Neurol. Neurosurg. Psychiatry 55, 181-184
		Hutchinson <i>et al.</i> (1999) J. Neurol. Neurosurg. Psychiatry 67, 815-818

Examiner: /Sahar Javanmard/	Date Considered: 09/02/2010
-----------------------------	-----------------------------

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.J./

<p>FORM HDP-1449 (Based on Form PTO-1449)</p> <p>PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)</p> <p>Sheet 5 of 6</p>	ATTORNEY DOCKET NO.	SERIAL NO.
	6102-000048/US/NP	10/593,964
	APPLICANT	
	Scheller, D., <i>et al.</i>	
	FILING DATE	GROUP
	September 22, 2006	1627

	Jackson <i>et al.</i> (1989) NaunynSchmiedeberg's <i>Arch. Pharmacol.</i> 340:35S365
	Joyce (2001) <i>Pharmacol. & Ther.</i> 90, 231-259
	Kitada (1998) <i>Nature</i> 392, 605-608
	Korczyn <i>et al.</i> (2002) <i>Drugs</i> 62(5), 775-786
	Krygowska-Wajs (2000) <i>Funct. Neurol.</i> 15, 41
	Kulkarni & Verma (1992) <i>Drugs of Today</i> 28(3):201-217
	Lee <i>et al.</i> (1982) <i>Psychiatry Research</i> 7, 111-119
	Levien (2005) <i>Advances in Pharmacy</i> 3(1), 62-92
	Li <i>et al.</i> (2000) <i>Proceed Intl. Symp. Control Rel. Bioact. Mater</i> , pp 952-953
	Li <i>et al.</i> (2001) <i>Pharm. Research</i> Vol. 18(11), 1509-1513
	Linazasoro (2004) <i>Movement Disorders</i> 19(7), 743-754
	Lucking (2000) <i>N. Engl. J. Med.</i> 342, 1560-1567
	Mackonochie (2003) March 31-April 3 Stuttgart, GER, Drug Discovery Tech. 2003 Seventh Annual Conference and Exhibition, Vol. 6, 420-422
	Matsumine (1997) <i>Am. J. Hum. Genet.</i> 60, 588
	Modigh <i>et al.</i> (1984) <i>Neurotransmitter & Receptor Mechanisms</i> , 18-27
	Mouradian & Chase (1989) <i>Curr. Opin. Neurol. Neurosurg.</i> 2:30-313
	Muramatsu <i>et al.</i> (2003) <i>GLIA</i> 42, 307-313
	Nair (2003) <i>Movement Disorders</i> 18(7); 738-750
	Nurse <i>et al.</i> (1984) <i>Neurochemical Research</i> 9(9), 1231-1238
	Nussbaum (2003) <i>N. Engl. J. Medicine</i> 348(14), 1356-1364
	Pankratz (2003) <i>Am. J. Hum. Genet.</i> 72, 1053-1057
	Park (2002) <i>Drug Delivery Technology</i> 2(5), July//August, http://www.drugdeliverytech.com/cgi-bin/issues.cgi?idIssue=6 and http://www.drugdeliverytech.com/cgi-bin/articles.cgi?idArticle=60
	Paulus & Trenkwalder (2006) <i>Lancet Neurol.</i> 5 (neurology.thelancet.com), 9 pp.
	Polymeropoulos (1997) <i>Science</i> 276, 2045-2047
	Prunier (2003) <i>NeuroImage</i> 19, 810-816
	Rammsayer (1997) <i>Int. J. Neurosci.</i> 91, 45
	Rascol, <i>et al.</i> (2002) "Treatment interventions for Parkinson's disease: an evidence based assessment." <i>Lancet</i> 359:1589-1598

Examiner: /Sahar Javanmard/	Date Considered: 09/02/2010
-----------------------------	-----------------------------

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.J./

FORM HDP-1449 (Based on Form PTO-1449) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) Sheet 6 of 6	ATTORNEY DOCKET NO.	SERIAL NO.
	6102-000048/US/NP	10/593,964
	APPLICANT	
	Scheller, D., <i>et al.</i>	
	FILING DATE	GROUP
	September 22, 2006	1627

	Riederer (2000) J. Neurol. 247(4), IV/36-IV/37
	Scriabine (2003) CNS Drug Reviews 9(4), 389-395
	Sharma (2002) Neurol. Clin. N. Am. 20, 759-778
	Stern (2004) Annals of Neurology 56(2), 169-170
	Stiasny-Kolster et al. (2000) SLEEP, May 1, 23(3), 1-6
	Stichel and Scheller (2005) EFNS Conference, "Rotigotine Prevents Neurodegeneration in a Mouse Model of Parkinson's Disease"
	Stockmeier <i>et al.</i> (1997) Neuropsychopharmacology 16(2), 162-173
	Strange (1993) Neurochem. Int. 22(3):223-236
	Swart (1993) Toxicology Methods 3, 279, 289 last paragraph
	Swart (1994) J. Analytical Toxicology 18, 71-77
	Swart (1995) Pharmaceutical Sciences 1, 437-440
	Tassin (1998) Am. J. Hum. Genet. 63, 88-94
	Timmerman (1993) Pharm. World Sci. 15(2):90-92
	Valente (2001) Am. J. Hum. Genet. 68, 895
	van der Geest <i>et al.</i> (1997) Pharm. Research Vol. 14, 1798-1803
	Van Duijn (2001) Am. J. Hum. Genet. 69, 629-634
	Vanacore (2002) Neurol. Sci. 23, S119
	Waters (2005) Movement Disorder 20(1), S38-S44
	Wikstrom (1992) in Ellis & Luscombe, eds. "Progress in Medical Chemistry" Vol. 29, pp. 199-216; Elsevier
	Office Action, dated September 12, 2008 issued in U.S. Application No.10/429,283
	Office Action, dated March 30, 2009 issued in U.S. Application No.10/429,283
	Office Action, dated December 23, 2009 issued in U.S. Application No.10/429,283
	Office Action, dated February 19, 2009 issued in U.S. Application No.10/585,609
	Office Action, dated September 14, 2009 issued in U.S. Application No.10/585,609
	Office Action, dated December 10, 2008 issued in U.S. Application No.11/060,997
	Office Action, dated June 29, 2009 issued in U.S. Application No.11/060,997
	Office Action, dated March 29, 2010 issued in U.S. Application No.11/060,997

Examiner: /Sahar Javanmard/	Date Considered: 09/02/2010
-----------------------------	-----------------------------

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.J./